Case update: Nutrition and health claims cases from the CJEU
The UK may have left the EU but decisions from the Court of Justice of the European Union ('CJEU') remain 'highly persuasive' when interpreting legislation which was formerly known as 'retained'. Furthermore, with the Sanitary and Phytosanitary Agreement ('SPS Agreement') on the horizon, dynamic alignment means that CJEU judgments will become more than persuasive when it comes to the in-scope legislation.
Regulation (EC) No 1924/2006 on nutrition and health claims made on foods ('NHCR') is assimilated law in Great Britain and reflected in the Advertising Codes enforced by the Advertising Standards Authority ('ASA'). The NHCR is also in scope of the SPS Agreement.
Two CJEU rulings from this autumn, Case C-657/24 Kyberg Pharma Vertriebs-GmbH v Schutzverband gegen Unwesen in der Wirtschaft eV and Vista-Life Pharma SA,Vista-Life Pharma Belgium SCRL v Laboratoires S.M.B. SA, Brussels Reps Pharma SRL Case C-721/24 are of interest in terms of interpretation of the NHCR.
Under the NHCR, a 'health claim' is defined as “any claim that states, suggests or implies that a relationship exists between a food category, a food or one of its constituents and health”. As well as stipulating that only health claims which are listed as authorised can be made for foods in Article 10(1), the NHCR requires in Article 10(2) that when making a health claim, specific information must be "included in the labelling, or if no such labelling exists, in the presentation and advertising". The information relevant to all types of health claim is:
(a) a statement indicating the importance of a varied and balanced diet and a healthy lifestyle;
(b) the quantity of the food and pattern of consumption required to obtain the claimed beneficial effect;
(c) where appropriate, a statement addressed to persons who should avoid using the food; and
(d) an appropriate warning for products that are likely to present a health risk if consumed to excess.
In addition, claims which are authorised as reduction of disease risk claims, must include a statement indicating that the disease to which the claim is referring has multiple risk factors and that altering one of these risk factors may or may not have a beneficial effect (Article 14(2)). Again, this risk factor wording must be on the labelling, or if no such labelling exists, in the presentation and advertising.
Is having the information on the labelling sufficient?
Kyberg Pharma sold food supplements which included a statement highlighting the importance of a varied and balanced diet on the labelling as required and ran advertisements in the written press. The Court was asked to decide whether this information was also required to be stated in an advertisement. The CJEU ruled that labelling and advertising were distinct and that written advertising to promote a food supplement does not come under the concept of 'labelling'. It went on to rule that if the mandatory information was included on the labelling, it did not also need to be included in written advertising.
The facts of this case specifically related to the mandatory information regarding the need for a balanced and varied diet whereas the Court’s ruling refers to Article 10(2) as a whole, so it doesn’t appear to be limited to that statement alone. It’s also worth noting that the judgment specifically refers to “written advertising”, which is undefined.
In Vista-Life the Court was also asked whether if advertising contained a reduction of disease risk claim, it was necessary to repeat the risk factor wording in written advertising if it was stated on the product label and if it was necessary to repeat the risk factor wording exactly as it was set out in the law. In line with the decision in Kyberg Pharma, the Court held that if the required information was on the label, it did not also need to be in the written advertising. It also confirmed that the wording did not need to be repeated exactly, as long as the two key points (there being multiple risk factors and altering one factor may or may not have a beneficial effect) were accurate, clear and easy to understand.
Essentially, required information only needs to be in the ad if it’s not on the labelling. This interpretation correlates with the position of the ASA in the UK, because the Advertising Codes do not include provisions requiring the information listed above to be in advertising.
Is it possible for dosage information to be a health claim?
Vista-Life ran advertisements in a periodical aimed at health professionals. The ads made claims that a daily dose of vitamin D supplements was better than a larger dose (“daily better than single dose”) and that the sublingual (under the tongue) method meant “more rapid absorption helps in avoiding the first-pass effect in the liver and enzymatic degradation in the gastrointestinal tract”. The claims were challenged on the basis that they were unauthorised health claims. The CJEU was asked whether statements relating to the frequency of intake and/or the method of administration of a food supplement fall within the concept of 'health claim'.
The Court held that where “practical matters are presented as being linked to a beneficial effect on health”, then references to the statements relating to the frequency of intake and/or the method of administration of a food supplement would fall within the concept of 'health claim'.
It’s worth remembering that while the ASA does not cover marketing communications in media addressed only to medical practitioners, that relate to those practitioners' expertise, statutory enforcers of the NHCR may still consider this ruling of interest.
Contact
Katharine Mason
Principal Associate
katharine.mason@brownejacobson.com
+44 (0)330 045 1382